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Enhancement or Recovery?





Scientific advancement has improved the human experience in nearly
every area of life imaginable. Even in ancient times, man has sought to im-
prove his existence through the use of tools and mechanisms for efficiency.'
In fact, one may phrase this desire as a race to find the next level of human
existence. The modern world provides many platforms for such a desire, and
the sports world is no exception. Scientific advancement plays a major role
in athletic performance. Discoveries in human anatomy and a careful study
of human kinetics have led athletes to try new substances and methods in an
attempt to gain a competitive edge over the competition. Recently, however,
a question has arisen: Has science gone too far with performance-enhancing
and performance-recovery substances? In the case of legislation, the United
States has made sharp distinctions as to which substances are legal.2 As we
move forward into the new millennium, we are discovering more about how
human anatomy functions. Thus, it is important that we reevaluate the
proper role of substances that promote recovery and enhance performance in
an ever-changing global society so the interests of athletes and others are best
served by the law.
The history of substance use in athletics dates back to ancient Greek and
Roman times. During the Olympic Games of 776 B.C. and gladiator compe-
titions, participants would often make use of stimulants like strychnine to
fight off fatigue and injury and to intensify their fights.3 In those times, such
substances were not banned and were used in many different forms prior to
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1. Around 3500 B.C., the wheel was originally created to serve as potter's wheels
in Mesopotamia. Megan Gambino, A Salute to the Wheel, SCIENCE & NATURE
(June 18, 2009), http://www.smithsonianmag.com/science-nature/A-Salute-to-
the-Wheel.html.
2. Office of National Drug Control Policy Reauthorization Act of 2006, Pub. L.
No. 109-469, 120 Stat. 3502 (2006)[hereinafter Drug Control Act]; Crime
Control Act of 1990, PL 101-647, 104 Stat. 4789 (1990)[hereinafter Crime
Control Act].
3. History of Performance Enhancing Drugs in Sports, HISTORICAL TIMELINE
(Sept. 14, 2011, 11 I:14 AM), [hereinafter History of PE Drugs] http://sport-
sanddrugs.procon.org/view.resource.php?resourcelD=002366; see also
Genevieve F.E. Birren & Jeremy C. Fransen, The Body and the Law: How
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competitions.4 However, modem substance abuse law concerns itself with
many substances derived from the human body's natural processes. 5 The
onset of high dollar winnings and earnings in competitive sports has incen-
tivized both athletes and scientists to seek out substances and methods that
allow for athletic improvement.
The discovery of new methods6 to introduce these substances into the
body and an increased awareness of the currently used substances have pro-
duced a growing demand to differentiate whether they enhance athletic per-
formance, assist athletes in recovery, or both. Furthermore, increased use of
these substances has created questions as to what degree these methods
should be regulated. Although recent use of anabolic steroids in professional
sports has been met with substantial negativity, such as Mark McGwire's
admission of steroid use during his professional baseball career, athletes ap-
pear reluctant to yield any ground to Congressional Acts. 7 Despite the ath-
letes' resistance to follow Congressional Acts, there are important scientific
and bio-ethical arguments surrounding substance use in professional sports.
This is particularly true with regard to performance enhancement and recov-
ery, which must be considered if professional sports are to transition into the
new millennium alongside scientific advancement.
An understanding of the biological effects of newly developed sub-
stances and methods is paramount to devising a proper legal standard for
their use. Human Growth Hormone ("HGH"), Erythropoietin ("EPO"), tes-
tosterone, gene therapy, Androgenic Anabolic Steroids ("AAS"), and over-
the-counter supplements are some of the most commonly used substances
and methods in today's sports world. A detailed look at what each of these
substances does for the human body will assist in determining whether they
should be banned from athletic performance. Furthermore, substances and
methods that interact with the human body differently than others may re-
quire different regulation.
Next, it is important to consider the current regulations regarding per-
formance-enhancing substances and methods. Throughout the last half-cen-
tury, different regulatory bodies and agencies, such as Congress and the
Physiological and Legal Obstacles Combine to Create Barriers to Accurate
Drug Testing, 19 MARQ. SPORTS L. REV. 253 (2008).
4. History of PE Drugs, supra note 3.
5. See generally Drug Control Act, supra note 2.
6. By "new methods," I am referring generally to nanotechnology being used by
pharmaceutical companies to formulate new drug delivery systems into the
human body. See, e.g., John C. Monica, Jr., NANOTECHNOLOGY LAW, § 5:28.
7. Mark McGwire continued the use of steroids in his professional baseball career
despite Congress' passage of the Anti-Drug Abuse Act of 1988, which banned
the use of steroids for non-medical purposes. See, e.g., Drug Enforcement
Agency Personnel Assignments., PL 100-690, § 9310, 102 Stat. 4181(1988)
[hereinafter Anti-Drug Abuse Act].
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World Anti-Doping Agency ("WADA"), have banned an ever-growing list
of substances and methods in both the athletic and public context.8 It is these
regulatory bodies and agencies that must pay close attention to advances in
science and technology to properly decide whether the new substances or
methods truly create an athletic advantage during competition. When a par-
ticular substance or method creates an advantage, regulators must decide how
to regulate that substance or method. They must also consider whether the
advantage to the athlete was born out of the attempt to rehabilitate an injury.
These considerations stem from a new method of performance-recovery
known as gene therapy.
Finally, the newly developed technique of gene therapy presents an in-
teresting inside look at how the future of performance-enhancement sub-
stances may be regulated. In the analysis, gene therapy is contrasted with
gene doping, which WADA defines as "[t]he non-therapeutic use of cells,
genes, genetic elements, or of the modulation of gene expression, having the
capacity to enhance athletic performance . . . ."9 Moreover, the case of Oscar
Pistorius provides a guiding example of how regulatory agencies can proce-
durally handle scientific advancements in sports.O Using the panel's analy-
sis from Pistorius's case, future courts will be able to better handle any
alleged violation of a substance regulation in athletics."
Overall, the rapid scientific advancements in substances and methods to
assist athletes in recovery come with many considerations for the athlete and
his or her team. Due to the lack of clarity on how performance-enhancing
substances will be regulated procedurally in the future, it is difficult for an
athlete, coach, parent, or agent to predict whether new developments or
methods will preclude the athlete from participating in competition. Athletes
should seriously consider whether they want to jeopardize their careers when
they choose to use new methods or substances to aid in recovery. On the
other hand, regulatory agencies must accept that scientific advancements and
the use of those advancements by athletes is not likely to stop any time soon.
Thus, in the future, the difference between what is considered performance-
enhancement and performance-recovery may become extremely clouded or
rendered moot.
8. Drug Control Act, supra note 2; Crime Control Act, supra note 2; World Anti-
Doping Agency, The World Anti-Doping Code: The 2008 Prohibited List In-
ternational Standard, 7 (2007), available at http://www.wada-ama.org/rtecon-
tent/document/2008_ListEn.pdf [hereinafter WADA Prohibited List].
9. WADA Prohibited List, supra note 8.
10. See generally Pistorius v. IAAF, Ct. of Arbitration for Sport, at 1-2, 6-7 Case
No. CAS 2008/A/1480, Arbitral Award (May 16, 2008), available at http:/
jurisprudence.tas-cas.org/sites/CaseLaw/Shared%20Documents/ 1480.pdf
[hereinafter CAS Arbitral Award].
11. Id.
4972012]
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II. HISTORY AND EVOLUTION OF PERFORMANCE-
ENHANCING SUBSTANCES
A. The Origin of Performance-Enhancing Substances
Although performance-enhancing substances are currently a subject of
much debate, such substances have been used for centuries without much
controversy. Dating as far back as 776 BC, the ancient Greek athletes were
using performance-enhancing substances when competing in the Olympic
Games.12 These substances were the most advanced for the era. Much like
today, this ancient society was one governed by law.
New creations and variations of commonly consumed substances be-
came more commonplace as athletes began searching for more creative ways
to sustain their energy levels. In the 19th century, French cyclists and la-
crosse players consumed a drink called Vin Mariani, which was a widely
used mixture of alkaloids, wine, and coca leaf extract-a source of cocaine.13
The drink's ingredients made it quite popular because it staved off the sense
of fatigue and hunger brought on by prolonged exertion.' 4
In the 20th century, athletes experimented with different combinations
of substances known to fight fatigue. For example, in the 1904 Olympics, a
marathon runner, Thomas Hicks, used a mixture of brandy and strychnine in
his competitions.15 In fact, using a combination of strychnine, heroin, co-
caine, and caffeine was a common practice among Olympic teams and
coaches until the 1920s when cocaine and heroin became only available by
prescription.16 However, in 1928, the first rule against the use of perform-
ance-enhancing substances was enacted by the International Association of
Athletics Federation ("IAAF"), the governing body for track and field. '7 The
IAAF made an interesting statement explaining that "[d]oping is the use of
any stimulant not normally employed to increase the poser of action in ath-
letic competition above the average."18 The implication was that as long as
use of the substance was commonplace among the athletes, then its use was
allowed and the athletes were on equal ground.19 Contrast this notion to to-
day's idea that any use of a banned performance-enhancement substance or





17. International Association of Athletics Federation, Drugs in Sport/Doping Con-
trol, lAAF MEDICAL MANUAL, http://www.iaaf.org/mm/Document/imported/
42026.pdf, (last visited Jan. 6, 2012).




method by an athlete, regardless of whether other athletes are also using it, is
a violation.
Subsequently, in the 1950's, some of the first performance-enhancing
substances, like amphetamines, widely used by soldiers in WWII, crossed
over into sports.20 Both Italian and Dutch cyclists used amphetamines to
minimize fatigue during exercise.21 In 1958, Dr. John Bosley Zieglar created
an anabolic steroid called Diaabol, subsequently released by Ciba
Pharmaceuticals with the Federal Drug Administration ("FDA") approval,
for sale in the United States.2 2 Dr. Zieglar's creation synthesized the
strength-building properties of testosterone while minimizing the negative
health effects of the hormone. 23 The use of amphetamines to combat a pre-
race illness led to the death of British Cyclist Tommy Simpson while he was
riding in the 13th stage of the Tour de France on July 13, 1967.24 His death
led the International Olympic Committee ("IOC") to establish its Medical
Commission to fight against doping in sports. 25 The Commission has three
guiding principles: protection of athletes' health, respect for medical and
sport ethics, and equality for all competing athletes.26 It is interesting to note
that these principles do not provide any guidance to what substances can or
cannot be used by the athletes despite the fact that they were enacted as a
reaction to an athlete's use of amphetamines.27
Eventually, in 1968, the IOC established its first compulsory drug test-
ing at the Winter Olympic Games in Grenoble, France and then instituted it
again at the Summer Olympic Games in Mexico City, Mexico that same
year.28 At the time, the list of banned substances included psychomotor stim-
ulants, miscellaneous central nervous system stimulants, narcotic analgesics,
and stimulants comprised of sympathomimetic amines and alcohol.29 At this
juncture, society began to view a commonplace and commercial substance,
like alcohol, as a substance that could potentially "enhance" performance and
thus should be banned for use in sporting events. However, this notion is in
direct opposition to the cyclists and lacrosse players of the 19th century, who
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legally consumed alcohol in the form of Vin Mariani in attempt to enhance
their performances.30
It is clear that society's notions of what is considered a performance-
enhancing substance has changed quite drastically over the span of several
centuries. Part of this change is due to advancements in science, biology,
and human anatomy. As those scientists and biologists discover more about
their respective fields, society's knowledge of the effects of certain sub-
stances or methods become more widely known. However, it seems this
knowledge has created more complications for regulating agencies.
B. Early Resistance To Performance-Enhancement
In the past few decades there has been a clear resistance to scientific
advancements in substances that not only assist an athlete in recovery but
also may improve his or her performance as a result of the recovery. Some
of the resistance has come in the form of legislation passed by Congress.31
As part of his War on Drugs program, President Ronald Reagan signed into
law the Anti-Drug Abuse Act of 1988 banning the sale and distribution of
steroids for non-medical purposes. 32 It is this act that established the impor-
tant distinction between a drug used for medical purposes and a drug used for
any other purpose.33 The importance of this distinction is that the drug's
chemical composition was not seen as an important factor in determining its
legality, but rather the purpose for which the drug was to be used.34 This
distinction between the purpose of the use of the substance or method and its
actual biological effects in the body continues to play a key role in determin-
ing an athlete's eligibility for competition.
In 1990, Congress strengthened its resistance to the use of performance-
enhancing drugs by passing the Anabolic Steroids Control Act, which added
steroids to the same legal class (Schedule III) as amphetamines,
methamphetamines, opium, and morphine.35 In this Act, Congress amended
Section 102 of the Controlled Substances Act and defined anabolic steroid to
mean "any drug or hormonal substance, chemically and pharmacologically
related to testosterone ... that promotes muscle growth ... "36 That is to
say, if a drug is chemically related to the body's natural hormone of testoster-
one and it promotes muscle growth, then such a drug is an anabolic steroid
30. Id.
31. Drug Control Act, supra note 2; Crime Control Act, supra note 2; Anti-Drug
Abuse Act, supra note 7.
32. Anti-Drug Abuse Act, supra note 7.
33. See id.
34. See id.
35. Crime Control Act, supra note 2.
36. Id., at Title XXI, § 1902 (amending Section 102 of the Controlled Substances
Act 21 U.S.C. 802).
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which may only be obtained by prescription.37 Here, Congress established
that drugs obtained via prescription are legal for use even though the drug
itself is not chemically different when used for performance-recovery
purposes.
In 1991, more resistance came in the form of the Major League Baseball
("MLB") Commissioner, Fay Vincent, who sent a seven page memo to all of
the major league teams on June 7, stating, "[tihe possession, sale or use of
any illegal drug or controlled substance by Major League players or person-
nel is strictly prohibited ... This prohibition applies to all illegal drugs and
controlled substances, including steroids."38 This went unnoticed by a major-
ity of the players and coaching staff involved in MLB.39 In 1997, MLB's
acting commissioner, Bud Selig, distributed a practically identical version of
the Fay Vincent memo, in which he cited steroids, that directed clubs to post
the policy in clubhouses and distribute copies of the memo to players.40 Se-
lig's memo also went largely ignored.41 This ignorance by MLB players in
regard to steroid or testosterone use demonstrated an early disregard for any
actions taken by regulating bodies to control the use of any substance that
may be considered to enhance an athlete's performance. However, in the
early 1990s, the range of substances available to athletes was not as large as
it is today. The fact that there is a greater volume of performance-enhancing
substances available complicates decision-making for both the athletes as
well as the regulating agencies. It is important to look deeper into the type of
effect substances have on human anatomy because it sheds light as to how
regulatory agencies may seek to handle their use by athletes.
C. Performance-Enhancing Substances and Their Biological Effects
At present, there is an array of substances available to athletes as well as
hospital patients recovering from an assortment of illnesses. Some of these
substances include HGH, EPO, testosterone, AAS, over-the-counter sub-
stances, and gene therapy or gene injections.42 It is important to note how
these substances affect human anatomy in order to pursue the ultimate goal
of determining their legality in sports.
37. Id.
38. Fay Vincent, Baseball's Drug Policy and Prevention Program, at 1-2, OFFICE
OF THE COMMISSIONER MAJOR LEAGUE BASEBALL (June 7, 1991) available at
http://sportsanddrugs.procon.org/sourcefiles/VincentMemo.pdf; History of PE
Drugs, supra note 3.
39. History of PE Drugs, supra note 3.
40. History of PE Drugs, supra note 3.
41. Id.
42. Brent S. Rushall & Guy Grant, HGH, EPO, Anabolic Steroids, and Testoster-
one in Swimming, AUSTRALIAN SWIMMING AND FITNESS, May-June 1998, at
42-44, http://coachsci.sdsu.edu/csa/vol56/fourdrug.htm [hereinafter PE Sub-
stances Article].
2012]
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First, HGH is a hormone that affects general growth.43 The most com-
mon HGH, Somatropin, acts on bones and muscles in a non-differential man-
ner.44 Through its best use, HGH may facilitate quicker overall recovery
from general fatigue.45 In triathlons and swimming, HGH is commonly used
in conjunction with anabolic steroids.46 The steroids provide specific adapta-
tion effects, and HGH assists in recovery. 47 HGH affects growth rate and has
beneficial medical uses and is used by athletes to "grow" larger but not nec-
essarily to enhance their abilities.48 The enhancement may be a result of
growing larger depending on whether or not it is beneficial to grow larger for
a particular sport. In professional tennis, in which I participated for two
years, growing taller can significantly help a player improve his or her per-
formance. This is because the extra height coupled with a longer reach al-
lows the player to move less to cover the same distance as a shorter player.
Over the time span of a match, the taller player would move significantly less
than the shorter player, leading to more fatigue for the shorter player. The
more fatigued player has a lower chance of winning the match. However,
depending on the sport, growing taller is not always an advantage.
Second, EPO, a hormone naturally produced in the body, signals the
bone marrow to begin the production of new red blood cells. 4 9 Natural pro-
duction of EPO can be created by training at high altitudes. 50 However, syn-
thetic EPO is a drug developed for the treatment of severe anemia, which
may develop from cancer treatments or HIV infections.51 EPO only lasts in
the body for a short time (as little as twenty-four hours), but its stimulus
effect continues for as long as two weeks due to the rise in oxygen in the
bloodstream.52 Its use is particularly attractive to individuals who participate
in primarily aerobic, fatiguing sports, such as cycling or running.53 The pred-
ecessor to EPO is known as blood doping-the transfusion of either donor






48. PE Substances Article, supra note 42.
49. Physiology of Altitude Training, HIGHER PEAK ALTITUDE TRAINING (last vis-
ited Jan. 06, 2012), http://www.higherpeak.com/faq-physiology.html [hereinaf-
ter High Altitude Training Article].
50. Id.
51. Id.




events by increasing the oxygen level in the bloodstream.54 Interestingly, it
doesn't seem to make a difference if an athlete uses high-altitude training or
synthetic EPO because both methods have the same effect. That is to say,
one can perform for longer periods of time with less fatigue because of the
excess amount of oxygen flowing through the bloodstream. However, too
much natural or synthetic EPO may "thicken" blood, which can cause addi-
tional circulatory strain and clotting in smaller blood vessels.55
Third, testosterone is available in natural and synthetic forms; synthetic
forms have different arrays of carbon-13 atoms than natural testosterone.5 6
Expressed as a ratio (T/E), a normal balance of testosterone to epitestoster-
one is roughly 1:1 (slightly higher for males and lower for females).57 Tes-
tosterone tends to increase strength and endurance levels in both males and
females when the T/E ratio is near or above 6:1.58 Recently, pharmaceutical
companies, such as Abbott, have been using different dosage amounts of
testosterone to treat low testosterone ("Low T") in males.59 This is interest-
ing because many times high-level athletes overtrain, causing them to experi-
ence chronic low-levels of testosterone. 60 Hence, the question arises: why is
an overtrained, high-level athlete with chronic low testosterone not allowed
testosterone supplementation, yet the Low T male can be prescribed an array
of testosterone treatment options?61 The answer is anything but clear. Here,
there is an interesting paradox. The average male with Low T can receive a
prescription from a doctor for testosterone supplementation and use it to re-
turn his testosterone to normal levels. However, the overtrained athlete, who
also has Low T, can obtain testosterone via prescription but runs the risk of
not being able to compete in competition should he use it to return his testos-
terone levels to normal.
54. John W. Orchard, Peter A. Fricker, Susan L. White, Louise M. Burke &
Deborah J Healey, The Use and Misuse of Performance-Enhancing Substances
in Sport, 184 (3) MED. J. AUSTL. 132-36 (2006), available at http://www.mja.
com.au/public/issues/184_03_060206/orc 10359_fm.html#0_i 1091800 [herein-
after Use & Misuse Article].




59. When a man's testosterone falls below a level of around 300 ng/dL, it's gener-
ally considered to be low. Abbott Laboratories, Is It Low T?, http://
www.isitlowt.com/what-is-low-t/signs-and-symptoms.html (last visited Jan. 08,
2012) [hereinafter Low TI.
60. J. Jurimae, A. Nurmekivi & T. Jurimae, Hormone Responses To Intensive In-
terval Training in Middle-Distance Runners, 21 BIOLOGY OF SPORT 1 (2004).
61. Describing several treatment options for men diagnosed with Low T: gels,
patches, injections, buccal tablets, and pellets. Low T, supra note 58, at http://
www.isitlowt.com/what-you-can-do/treatment-options.html.
2012]
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Fourth, "AASs are specialized derivatives of the male hormone testos-
terone."62 "They increase protein synthesis and when coupled with training
and proper nutrition increase lean muscle mass."63 There are many types of
AASs for different medical uses and not all AASs are performance-enhanc-
ing.64 However, some AASs enhance strength, tolerance for anaerobic work,
and shorten the body's recovery time.65 They respond differently to specific
bodily stresses, and thus, produce augmentations in the functioning of locally
stressed body parts.66 This is the substance rumored to have been circulating
throughout MLB players for the past couple decades.
Fifth, over-the-counter supplements are considered "legal" under anti-
doping codes; however, there are some controversies due to the notion that
they may enhance athletic performance.67 Though there is no specific scien-
tific evidence to support the benefits claimed for many of these over-the-
counter products, there is substantial proof that some can enhance perform-
ance when used according to particular procedures. 68 For instance, athletes
taking caffeine, creatine, or bicarbonate/citrate can exercise at a more intense
level for a greater time before they begin to experience fatigue.69 In response
to attempts to regulate such products, WADA has contemplated that such
ingredients occur naturally in food and that manufactured over-the-counter
products merely represent a practical way for athletes to consume a certain
dosage of those ingredients.70 Contrarily, the WADA Code has banned
prohormones, including Androstenedione, Dehydroepiandrosterone, and 19-
Norandrostenedione, which all can be converted in the body to testosterone
or the anabolic steroid Nandrolone.71 Nevertheless, the Dietary Supplement
Health and Education Act of 1994 allowed products containing prohormones
to be marketed as over-the-counter dietary supplements due to the amino acid
content present in the prohormones.72 It seems as though WADA and Con-
gress disagree as to whether products containing prohormones are worth
banning.










72. Dietary Supplement Health and Education Act of 1994, Pub, L No. 103-417,
§ 201, 108 Stat. 4325 (1994) [hereinafter Supplement Act].
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Sixth, gene therapy, also known as gene injections, is a relatively new
development and is on the cutting edge of performance-enhancement. Gene
injections are performed when one injects into muscles a manipulated virus
that carries a gene for insulin-like growth factor 1, also known as IGFI,
which has caused target muscles in rats to grow in size and strength by fif-
teen to thirty percent. 73 The inserted gene causes formation of extra IGF1,
which causes the growth of muscle cells.74 When the technique was used on
rats that were put through an exercise program, the rats doubled their muscle
strength.75 Lee Sweeney, who conducted a study regarding gene injections at
the University of Pennsylvania, stated:
If a normal person would inject this, their muscles would get stronger
without them doing anything . . . If they are athletes in training, the rat study
indicates that their training would be much more effective, injury would be
overcome more easily and the effect of the training would last a much longer
time.76
The effects appeared to last throughout the entirety of the rats' life.77
The technique was designed so that the IGF1 gene stays in the target muscle
and does not move into the bloodstream where it could cause damage to
other organs. 78 Bio-nanotechnology, such as these performance-enhancing
gene injections, presents a new frontier in both science and law as both fields
will eventually need to grapple with this new advancement. As of now, there
is no precedent regarding gene therapy that would assist regulatory agencies
on how to approach a situation where an athlete is receiving gene therapy for
recovery purposes. It is advancements like gene therapy that require regula-
tory agencies to constantly evaluate where to draw the line between perform-
ance enhancement and performance recovery.
Il. CURRENT LEGAL STATE OF PERFORMANCE-
ENHANCING SUBSTANCES
A. The Fight Against Performance-Enhancing Substances
The prevailing view of athletes using any substance deemed to enhance
athletic performance has continued to move more toward the negative. That
is to say, these substances and their use by athletes in competition have be-
come progressively more regulated. For instance, in February 1999, the
73. Paul Recer, Gene Therapy Creates Super-muscles, GENETICS ON MSNBC.
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World Conference on Doping in Sport, held in Lausanne, produced the Lau-
sanne Declaration on Doping in Sport.79 This declaration created an indepen-
dent, international anti-doping agency, which was to be fully operational for
the XXVII Olympic Games in Sydney in 2000.80 Pursuant to the document's
terms, WADA was established in 1999 to promote and coordinate the fight
against doping in sports worldwide.81 WADA was created as a foundation
under the initiative of the IOC with the support and participation of govern-
ments, intergovernmental organizations, public authorities, and other public
and private bodies who opposed doping in sports.82 WADA consists of sev-
eral equal representatives from the Olympic Movement as well as public
authorities.83
Moreover, the United States Anti-Doping Agency ("USADA"), the in-
dependent anti-doping agency for Olympic sports in the United States, was
created as a the result of recommendations set forth by the United States
Olympic Committee's Select Task Force on Externalization.84 The USADA
initiated operations on Oct. 1, 2000, and maintained full authority for testing,
education, research, and adjudication for U.S. Olympic, Pan Am, and
Paralympic athletes.85 The USADA's responsibility was to develop a com-
prehensive United States anti-doping program for the Olympic Movement. 86
The creation of many different national and international regulatory bodies
over recent years demonstrates the seriousness with which society treats per-
formance-enhancing substances. This seriousness is a far cry from the un-
regulated sports world of the 19th century. Clearly, the new millennium has
brought about a more strict view of the use of performance-enhancing sub-
stances via the creation of WADA and the USADA.
On Dec. 29, 2006, in furtherance of this strict view, President Bush
signed into law HR 6344, the Office of National Drug Control Policy
Reauthorization Act of 2006, which prohibits the use of gene-doping and
bans the use of genetic modification for performance enhancement in ama-
teur athletic competition recognized by the U.S. Olympic Committee.87 No-
tice that this act only prohibits "gene doping" and not "gene therapy."88 The
Reauthorization Act may see more action in years to come due to the ad-






85. History of PE Drugs, supra note 3.
86. Id.




vancements in bio-nanotechnology. Advancements may eventually make it
easier for athletes to make genetic changes to their bodies for either perform-
ance-enhancing or recovery purposes. Should athletes begin using advanced
bio-technology on a large scale, a different type of regulation or an amend-
ment to the Reauthorization Act may be necessary to clearly establish
whether any form of gene therapy is banned from use in sports.
In contrast, in 2004, WADA removed caffeine from its list of banned
substances.89 Interestingly enough, some doctors believe WADA legalized
caffeine because research demonstrated that caffeine exceeding the amount
allowed under the WADA rules may actually decrease performance.90 Fur-
thermore, doctors believed WADA wanted to avoid undue punishment for
athletes whose bodies metabolize caffeine at different rates. 91 The removal
of caffeine from WADA's banned substances list demonstrates an interest by
governing authorities in looking deeper into whether these different sub-
stances actually improve athletic performance. This type of in-depth analysis
is a beneficial practice that should continue for each substance in order to
truly determine whether some substances are in fact both performance-en-
hancement and performance-recovery drugs.
B. Crossing the Line Leads to Litigation and Settlements
The recent onslaught of regulation overseeing performance-enhancing
substances in athletics did not deter some athletes from their use. In the
recent decades some athletes have been in the spotlight of the performance-
enhancement substance debate. Both Barry Bonds and Lance Armstrong
have found themselves involved in either litigation or allegations regarding
using these substances while competing in professional athletics.92 It is im-
portant to understand the basics of each athlete's situation in order to further
analyze the performance-enhancing substances debate.
Barry Bonds is a former MLB outfielder, who played from 1986 to
2007, for the Pittsburgh Pirates and San Francisco Giants.93 He debuted in
1986 with the Pittsburgh Pirates and joined the San Francisco Giants in 1993,
where he remained through the 2007 season. He has had a controversial
89. Anna Salleh, Athletes' Caffeine Use Reignites Scientific Debate, ABC SCIENCE




92. United States v. Bonds, No. CR 07-00732 SI, 2009 WL 416445 (N.D. Cal. Feb.
19, 2009), aff'd, 608 F.3d 495 (9th Cir. 2010); see also Tom Goldman, Ex-
Friends Say Armstrong Admitted Drug Use, NPR.oRG (June 24, 2006), http://
www.npr.org/templates/story/story.php?storyld=5508863 [hereinafter NPR
Armstrong Article].
93. Barry Bonds Statistics and History, BASEBALL-REFERENCE.COM, http://www.
baseball-reference.com/players/b/bondsba0l.shtml (last visited Sept. 1, 2012).
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career, notably as a central figure in baseball's steroids scandal. In 2008, he
was indicted on charges of perjury under 18 U.S.C. §1623(a) and obstruction
of justice under 18 U.S.C. § 1503 for allegedly lying to the grand jury during
the government's investigation of Bay Area Laboratory Co-operative
("BALCO").94 Bonds testified that he never knowingly took illegal ster-
oids.95 Specifically, he was accused of lying when he said he did not know-
ingly take the -steroids given to him by his former trainer Greg Anderson and
that Anderson never injected him with steroids.96 The trial began March 21,
2011, and he was convicted on April 13, 2011, on the obstruction of justice
charge.97
Even though the charges against Bonds centered on perjury and obstruc-
tion of justice, the true reason Bonds was in this position was his involve-
ment with BALCO, which was in the business of selling what many
considered performance-enhancing substances.98 Bonds initially became in-
volved in the scandal through his trainer, Greg Anderson, who was indicted
by a federal grand jury in the United States District Court for the Northern
District of California and charged with supplying anabolic steroids to ath-
letes.99 Since Anderson had been Bonds's trainer circa 2000, there was spec-
ulation about whether Bonds had used any performance-enhancing
substances while playing in the Major Leagues.0o The speculation centered
on his possible use of anabolic steroids.O1 Bonds denied having ever having
knowingly used anabolic steroids at any point, either for recovery or per-
formance-enhancement purposes.102
However, even if Bonds had admitted to using anabolic steroids, the
larger questions become: to what extent is the use of anabolic steroids
banned in sports and should there be a new "limit" on their use if they are so
prevalent that testing for them becomes too high a cost to the professional
sports leagues? The answer to the first question is clear because anabolic
steroids are banned in sports.103 However, the answer to the second question
is not clear. Regulating agencies, especially the MLB, need to take an in-
94. United States v. Bonds, 608 F.3d 495, 499 (9th Cir. 2010).
95. Id.
96. Id.; Lester Munson, Last, Best Hope in Convicting Bonds, ESPN.coM (Apr. 6,
2011), http://sports.espn.go.com/espn/otl/columns/story?id=6301745.
97. Juliet Macur, Bonds Guilty of Obstruction, but Not of Perjury, N.Y. TIMES,
Apr. 13, 2011, at A 1, http://www.nytimes.com/2011/04/14/sports/baseball/ 14
bonds.html.
98. Bonds, WL 416445, at * 1.
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depth look into whether banning anabolic steroid use altogether is cost effec-
tive for the sport. Furthermore, they need to consider balancing between
high testing costs and what consequences' 04 may occur should they allow a
limited use of anabolic steroids.
Another athlete recognized worldwide, Lance Armstrong, faced allega-
tions from across the globe regarding use of performance-enhancing sub-
stances. Specifically, in 2006, French newspaper Le Monde reported claims
by Betsy and Frankie Andreu during a deposition that Armstrong had admit-
ted using performance-enhancing drugs to his physician just after brain sur-
gery in 1996.105 The Andreus' testimony related to litigation between
Armstrong and SCA Promotions, a Texas company attempting to withhold a
$5 million bonus. This case was settled out of court with SCA paying Arm-
strong and Tailwind Sports $7.5 million, to cover the $5 million bonus plus
interest and lawyers' fees.106 Relevant testimony was as follows: "And so the
doctor asked him a few questions, not many, and then one of the questions he
asked was . . . have you ever used any performance-enhancing drugs? And
Lance said yes. And the doctor asked, what were they? And Lance said,
growth hormone, cortisone, EPO, steroids and testosterone."0 7 Armstrong
suggested Betsy Andreu may have been confused by questions about his
post-operative treatment, which included steroids and EPO, taken to counter-
act wasting and red-blood-cell-destroying effects of intensive
chemotherapy. 108
As this instance demonstrates, much of what has been claimed regarding
Armstrong's use of performance-enhancing substances has centered on pos-
sible use of EPO and testosterone. 09 Yet, many may not consider the possi-
bility that Armstrong's use of these substances were for chemotherapy
treatment recovery only and not to enhance his athletic performance.10
These allegations and the ensuing answers from Armstrong bring about an
interesting legal paradox regarding steroids, testosterone, and EPO use
among athletes. The paradox is that the use of steroids and EPO are not
considered illegal when used in a recovery context, such as treating patients
with anemia.l, However, the use of these substances to recover from ex-
104. By "consequences," I am referring to what unintended effects allowing a lim-
ited use of anabolic steroids may have on younger aspiring baseball players.






Ill. "Although the Olympic Committee bans EPO from competition, the drug is
safe in humans and is already approved by the FDA to treat anemia, especially
in patients with cancer or kidney failure." Laurie Barclay, Blood Builder Of-
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hausting endurance-based sports, which at a professional level often puts ath-
letes' bodies in an overstrained state, is banned even though the substances
are chemically equivalent to those used in recovery. "12
It is unclear what the intention of the regulating bodies is when such a
paradox exists. The paradox calls for a more structured procedure on how to
determine what exactly is considered a performance-enhancing substance or
method versus what is determined to be a performance-recovery substance or
method. Alternatively, there may not be a difference between performance-
enhancement and performance-recovery in some instances such as the use of
gene therapy.
IV. ANALYSIS
A. Flawed Concept of a Difference Between Enhancement and
Recovery
Due to advancements such as biotechnology as well as high profiled
allegations of performance-enhancing substance use, the question arises:
where should Congress or other regulatory agencies draw the line between a
performance-enhancement substance and a recovery substance? Lance Arm-
strong's answer to allegations of performance-enhancing substance use
brings about that dispute."13 Doctors questioned Armstrong as to whether he
had ever used performance-enhancing substances." 4 His answer was
"Yes."'15 However, according to Armstrong, he had used them in an attempt
to recover from chemotherapy., 16 Thus, the answer to the aforementioned
question depends on whether one considers the context in which the sub-
stances are used. Say, for example, a professional athlete is severely fatigued
after a sporting event (hours, days, even weeks long) and that athlete uses
EPO as a recovery method, which in turn enhances his or her performance
for the next event because they are closer to being fully recuperated. In this
instance, is EPO being used as recovery, enhancement, or both? Regardless,
EPO is banned by WADA, which precludes international athletes from using
it.17 On the other hand, in a hospital context, the use of EPO would likely be
considered only a recovery substance for anemia patients.Is In that context,
fers New Hope for Brain Diseases, WEBMD HEALTH NEWS (Aug. 10, 2001),
http://www.webmd.com/brain/news/20010810/blood-builder-offers-new-hope-
for-brain-diseases [hereinafter EPO Article].
112. See, id.




117. WADA Prohibited List, supra note 8.
118. EPO Article, supra note 110.
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use of EPO is not criminalized or banned.119 Interestingly, EPO does not
have to be adjusted much chemically in order for it to be used for perform-
ance-enhancement or anemia patient recovery.120 Hence, the only variable in
those two situations is how one chooses to view EPO's use. Ultimately, the
legal line is drawn based on the user's purpose for the use of the substance or
method.
A consensus exists in professional sports that an athlete using perform-
ance-enhancing substances creates an unfair advantage for that athlete be-
cause other competitors are not using such substances. Thus, WADA and
Congress have banned certain substances so as to level the playing field and
prevent deteriorating health. 12' However, many items could possibly be con-
sidered "performance-enhancing" as well as recovery products. For exam-
ple, drinking a sports-drink like Gatorade after a workout enhances
performance in a subsequent workout because it replenishes the body with
lost electrolytes the body needs to function properly.122 Lactic acid build-up
creates soreness that may hinder an athlete in the next event. Thus, drinking
a Gatorade after a workout or practice enhances one's athletic performance
by assisting the body in recovery and allowing that athlete to perform closer
to one hundred percent.
There are many substances that purport to assist one's body in recovery
that could also be considered both recovery and enhancement products.123
This fact raises the question, why ban other substances, such as EPO, testos-
terone, and HGH if all these substances do is assist the body in recovery?
The banned substances are, in theory, merely an advanced version of what
Gatorade and a plethora of other over-the-counter products purport to be: a
workout recovery product. EPO, HGH, and testosterone not only assist in
physical recovery, but also allow the body to function properly; as evidenced
by the use of EPO in treating anemic patients and testosterone used to treat
older males diagnosed with "Low T."124 Furthermore, many drugs used to
assist sick patients in recovery are chemically equivalent to the "banned sub-
119. See id.
120. See generally id.
121. Drug Control Act, supra note 2; Anti-Drug Abuse Act, supra note 7; WADA
Prohibited List, supra note 8.
122. See Ronald Maughan, John B. Leiper & Susan M. Shirrefs, Rehydration and
Recovery After Exercise, 9 SPORTS Sci. EXCH. No. 3 (1996), available at http:/f
www.gssiweb.com/Article-Detail.aspx?articleid=35&level=2&topic=2 [here-
inafter Rehydration & Recovery].
123. See generally Rehydration & Recovery, supra note 121; see e.g., AdvoCare
International, L.P., Rehydrate, available at http://www.advocare.com/products/
active/A2412.aspx; see also Optimum Nutrition, Inc., 2:1:1 Recovery, availa-
ble at http://www.optimumnutfition.com/products/211 -recovery-p-252.html.
124. EPO Article, supra note 110; Low T, supra note 59.
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stances" athletes are using to recover from competitions.25 Therefore, there
may not be a bright line between what really is a performance-enhancing
substance and a performance-recovery substance. A specific bright-line must
be drawn to determine what exactly is unjust about substances that increase
performance by assisting the athletes in recovery.
Where is that bright-line drawn? The answer to this question may be
simple in theory, but difficult to implement. For instance, EPO and high-
altitude training produce a similar effect for an athlete in that the athlete is
able to perform for longer periods of time due to the increased amount of
oxygen in his or her bloodstream. 126 It assists both in recovery and perform-
ance-enhancement because the more oxygen present in the bloodstream, the
faster an athlete can recover. The athlete in turn performs better for the next
event. The result from using EPO creates an unclear reason as to why sub-
stances are lumped into either a performance-enhancing category or a per-
formance-recovery category. Ultimately, these substances are really
assisting in both functions. Substances such as EPO and testosterone assist
in recovery, which in turn allows one to enhance their performance as a by-
product of the recovery purpose for which those substances were originally
taken.
For EPO in particular, the bright-line to be drawn is exacted by deter-
mining how much EPO use produces a result equal to the average, and rec-
ommended, time spent in high-altitude training.127 Once that amount is
determined, then it is safe to say there is no difference between which
method the athlete uses to increase endurance (provided the athlete does not
over-do either method and cause harm to their bodies). However, it is at this
point where implementing such exact measurements becomes difficult. For
example, female and male athletes each have individual body types and sizes,
which creates complications for determining a "one-size fits all" amount of
EPO to be allowed by regulatory bodies such as Congress or WADA. The
amount of EPO that a cyclist may require could differ drastically from the
amount a National Football League player could require due to many factors
such as size, metabolism, weight or length of play. The same difficulties
would apply to finding a bright-line rule for testosterone use as well.
There are no easy answers, but since performance enhancement and re-
covery are really just a matter of degree, perhaps a solution can be proposed.
First, more specifically defining why substances are banned or outlawed will
assist rule-making agencies in determining which substances should be
banned. For example, if Congress, WADA, or the IOC were to define a
banned substance by specifying the level of dosage allowed in the body, then
substances like EPO, HGH, and testosterone could be legalized and regulated
by WADA, IOC, or other professional sport organizations. This is similar to
125. See id.




the method used for bloodstream alcohol levels pertaining to drinking and
driving as well as to pharmaceutical drugs. Pharmaceutical drugs are bought,
sold, and used every day to recover/enhance people's bodies. If sport gov-
erning bodies were to set a dosage level for products such as EPO, HGH, and
testosterone, as has already been done in the medical field, then these sub-
stances may be legalized and used as part of recovery for athletes. This
method, of course, would require testing of every athlete prior to every com-
petition, which would be costly. Here, sports organizations grapple with the
cost of such a solution versus banning the substances all together. Ulti-
mately, the question the organizations must ask themselves is "which solu-
tion costs us less and still maintains a high reputation with potential players
in our leagues"?
The law could regulate such a method in sports much like regulation of
the pharmaceutical industry, for which there is already a system in place.128
In fact, the regulations or body of law for this type of solution may be easier
than using the current testing methods since efficient dosage calculations are
already being performed by pharmaceutical companies.29 Hence, the transi-
tion of dosage amounts and its accounting method would merely be trans-
ferred to governing bodies such as WADA or the IOC and that transition
would be relatively seamless.
There is not a significant difference between substances that enhance
performance and ones that assist in recovery. This is important because even
though legislation has already been passed banning certain substances known
to enhance or assist in recovery for humans in the sporting context, bi-
otechnological advancements may force Congress to regulate such use be-
yond sports. For example, the passage of the Drug Control Act of 2006,
which prohibits the use of gene doping and bans from athletic competition
anyone who uses genetic modification for performance-enhancement, is not
currently the center of any litigation.30 It is important to take note, however,
that this lack of litigation may not be the case for much longer. The advance-
ment of biotechnology worldwide is moving at a fast pace and will inevitably
make its way into the field of athletics as athletes seek to compete at a higher
level. The situation then will become more complicated. Will Congress or
regulatory agencies allow biotechnology to be used in sports, the medical
field, agriculture, or even technology? And, if Congress and regulatory
agencies do allow such biotechnology to be used in those different fields,
how does that affect the future of professional sports, medicine, food supply,
and technology?
The answer to that question can only partly be answered with regard to
professional sports. Already, in 2008, WADA banned the use of biotechnol-
128. 1 Food and Drug Admin. § 13:2 (2012).
129. See Drug Dose Calculations Made Easier, http://www.davesems.com/files/
drug-dose calculations.pdf (last visited Sept. 9, 2012).
130. Drug Control Act, supra note 2.
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ogy in the form of gene doping from competition and sports. 131 However,
judging from the past use of banned substances, athletes will probably find a
way to effectively use biotechnology, such as gene doping, in competition.
Interestingly, The Office of National Drug Control Policy Reauthorization
Act of 2006, which bans gene doping, may be ahead of its time because it
may address a large portion of soon-to-be claims against athletes attempting
to gene dope.132 On the other hand, gene doping may advance beyond the
detection abilities of the overseeing bodies in sports. These scientific ad-
vances may create an arms-race between substance use and detection. Such
an arms race calls for legal clarification on how to handle biotechnology, and
more specifically, how to handle gene doping. Another issue is the need to
closely examine whether there is truly a difference between gene doping and
a new form of recovery from injury known as gene therapy.
B. Gene Doping Versus Gene Therapy: Case In Point
Gene doping, which WADA defines as "[t]he non-therapeutic use of
genes, genetic elements and/or cells that have the capacity to enhance athletic
performance . . . ." has been banned by both WADA and The Office of
National Drug Control Policy Reauthorization Act of 2006.133 There is a
difficult distinction between gene therapy, which is the use of genetic mate-
rial for recovery purposes, and prohibited gene doping in athletes.134 For
instance, gene therapy is performed in order to correct genetic abnormalities
and to repair sports injuries, but such therapy may also genetically enhance
the athlete, which renders moot the distinction between gene therapy and
gene doping.135 This presents an athlete, who must receive gene therapy for
recovery purposes, with a dilemma due to the potential genetic and perform-
ance enhancements that may be a result of such gene therapy. Such a distinc-
tion exemplifies the difficulty of determining whether such methods are
considered to be a recovery or enhancement mechanism for athletes.
First, explanation and examples of both gene therapy and gene doping
are important to explore prior to discussing whether such methods are truly
distinct. Gene Therapy is a technique for correcting defective genes respon-
sible for disease development. 36 Numerous diseases are a result of unusual
DNA variations, which are caused by an abnormality in protein production
131. WADA Prohibited List, supra note 8.
132. Drug Control Act, supra note 2.
133. WADA Prohibited List, supra note 8; see also Drug Control Act, supra note 2.
134. Kristin Jo Custer, From Mice to Men: Genetic Doping in International Sports,
30 HASTINGS INT'L & COMP. L. REV. 181, 206 (2007).
135. See id.
136. Human Genome Project (HGP) Information, Gene Therapy, http://www.oml.
gov/sci/techresources/HumanGenome/medicine/genetherapy.shtml (last vis-
ited Sept. 9, 2012).
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and function within the cells. 137 Gene therapy occurs when genetic scientists
are able to determine the specific genes involved in diseases, relate the spe-
cific genes to certain diseases, and ultimately insert a "normal" gene into
human cells to substitute for or supplement a defective gene.138 This method
has been used to treat both disease and, more recently, sports injuries.139 In
many sports injuries, there is a major concern with tissue trauma, which usu-
ally occurs in the form of torn ligaments, tendons, cartilage, and muscle. 140
Since these types of injuries heal slowly, there is an increasing interest in
utilizing gene therapy for faster recovery. 14, Gene therapy, however, be-
comes enhancement "(1) when it is undertaken for the purpose of improving
a characteristic or capability that, but for the enhancement, would lie within
what is generally accepted as a 'normal' range for humans; or (2) when it
installs a characteristic or capability that is not normally present in
humans."142 For example, gene doping can occur when an athlete attempts to
enhance muscle strength through use of IGF-I gene therapy, which can create
"genetically inflated musculature" allowing for increases in muscle endur-
ance for aerobic exercise and increase fast-twitch muscle fibers in anaerobic
exercise.143 This would allow athletes to enhance a specific muscle group
based on what their particular sport requires of them, such as a cyclist's
quadriceps, a swimmer's shoulders, or a sprinter's hamstrings.
Naturally, the question becomes: what is the difference between gene
therapy and gene doping? Differentiation between gene therapy and gene
doping can be difficult because both encompass the same genes, employ the
same techniques, and yield similar outcomes. The purpose behind the two
ideas is what separates them in society's mind. Gene therapy involves re-
pairing or recovering, while gene doping is considered to "enhance" human
ability beyond that of what is considered "normal." Paradoxically, when
gene therapy is used to assist an athlete in recovery or repair, that athlete has
in essence received an enhancement. Thus, there is a potential for ambiguity
between the two and athletes receiving gene therapy treatment for disease or
injury may have reason for concern regarding their eligibility to compete.
137. Human Genome Project (HGP) Information, Gene Disease Information, http://
www.ornl.gov/sciltechresources/HumanGenome/medicine/assist.shtml (last
visited Feb. 01, 2012) [hereinafter HGP Gene Therapy].
138. Human Genome Project (HGP) Information, Gene Therapy, supra note 135.
139. Vladimir Martinek et al., Gene Therapy and Tissue Engineering in Sports
Medicine, 28 THE PHYSICIAN AND SPORTSMED 34, 34-41 (2000), available at
http://www.sportgen.narod.ru/genter.htm.
140. See generally id.
141. See generally id.
142. Maxwell J. Mehlman, The Law of Above Averages: Leveling the New Genetic
Enhancement Playing Field, 85 IOWA L. REv. 517, 523 (2000).
143. H. Lee Sweeney, Gene Doping, Sci. AM., July 2004, at 69.
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Regulations currently in place need further scrutiny in order to properly deal
with this problem.
The regulations and their application to gene therapy are important to
understand in order to discern a true difference between gene therapy and
gene doping. The two leading regulatory authorities overseeing gene doping
are the IOC and WADA. By mid-year in 2001, the IOC Medical Commis-
sion began including gene doping in their discussions and on January 1,
2003, the IOC became the first institution to ban gene doping by adding it to
its list of prohibited substances and methods for international competition.I 44
The next year, WADA took responsibility for updating the list of prohibited
substances even though the JOC still maintains representation within WADA
committees through the IOC Medical Commission.145 The IOC created a
tribunal, the Court of Arbitration for Sport ("CAS"), to handle and resolve
legal issues in international sports through the use of arbitration and media-
tion.146 Even though the IOC created the CAS, this arbitral body is used by
nearly all Olympic International Sports Federations and their statutes man-
date that disputes be directed toward the CAS for arbitration.147 In the
United States 21 U.S.C. § 2001 mandates the United States Anti-Doping
Agency work with the United States Olympic Committee to help ensure ath-
letes in amateur athletics are "prevented from using ... performance-enhanc-
ing genetic modification accomplished through gene doping."148
Additionally, the statute dictates that the Agency is to "permanently include
'gene doping' among any list of prohibited substances adopted by the
Agency."149 Furthermore, a landmark in anti-doping took place when the
WADA Prohibited List included a prohibition against gene doping, even
though gene doping was not yet in use. 150 The 2008 WADA Prohibited List
explicitly prohibits gene doping, which is defined as "[t]he non-therapeutic
use of cells, genes, genetic elements and/or cells that have the capacity to
enhance athletic performance .... "151 A major concern with these regula-
tions is that because gene therapy and gene doping use the same methods,
144. 0. De Hon, P. Sollie, & J. Vorstenbosch, Gene Doping, NECEDO NETHERLANDS
CENTRE FOR DOPING AFFAIRS, February 2004, http://www.dopingautoriteit.nl/
medialfiles/documenten/2009/Gene%2ODoping.pdf
145. See Custer, supra note 134, at 190.
146. The International Council Of Arbitration for Sport and the Court of Arbitration
for Sport (CAS), Statutes of the Bodies Working for the Settlement of Sports-
related Disputes 1, 4, 5, 12 (2004), available at http://www.tas-cas.org/d2w
files/documentl281/5048/0/3.1%2OCodeEngnov2004.pdf.
147. Custer, supra note 134, at 191.
148. 21 U.S.C. § 2001(b)(2) (2006).
149. 21 U.S.C. § 2001(b)(5) (2006).




there is no clear bright line separating the two outside of an athlete's own
description of the purpose behind the gene therapy. It is unclear as to how
these current regulations can be applied.
Two problems anchor the debate between what is performance recovery
and what is performance-enhancement with regard to gene therapy and gene
doping. First, future testing for gene doping is unlikely to be able to distin-
guish between the protein expressions in gene doping and those in gene ther-
apy. Thus, some athletes may be wrongly sanctioned if the tests come back
positive. This problem leads to the second concern, which is that gene ther-
apy may enhance certain muscles or tissues even though that may not have
been the intention of the treatment. Gene therapy as a treatment is unlike
other methods or substances, with which the regulatory bodies are familiar,
and may pose complications in testing in the near future.
The second problem demonstrates the heart of the debate between per-
formance-enhancing and performance-recovery substances. The concern
with current gene doping regulations is how the phrase "enhance athletic
performance" will be evaluated or interpreted going forward.152 Both the
WADA Prohibited List as well as 21 U.S.C. § 2001 indicate that athletic
performance-enhancement is not prohibited as long as gene therapy is the
purpose for such manipulation.]53 Nevertheless, it is likely that whenever a
person receives gene therapy, whether for disease treatment or sports injury
repair, there will be some type of "performance-enhancing genetic modifica-
tion."154 Thus, an athlete receiving gene therapy as a treatment for a condi-
tion will obtain enhancements in their ability to perform. Unfortunately, the
current regulations do not explain how gene therapy is to be settled with any
sort of enhancement by-product of the gene therapy.155 Moreover, agencies
such as IOC and WADA have not specifically addressed how they intend to
determine whether it is gene therapy or gene doping that is the cause of any
performance-enhancement.156 Additionally, the Therapeutic Use Exemption
in the WADA World Anti-Doping Code may or may not apply to gene ther-
apy, creating more confusion.157
Such confusion may complicate how different regulatory agencies de-
cide what is performance-enhancement and what is performance-recovery.
152. See WADA Prohibited List, supra note 8.
153. See 21 U.S.C. § 2001(b)(2) (2006); see also WADA Prohibited List, supra note
8.
154. 21 U.S.C. § 2001(b)(2) (2006).
155. Custer, supra note 134, at 206-07.
156. See Custer, supra note 134 at 209.
157. Therapeutic Use Exemption will allow an athlete with a documented medical
condition to use one of the prohibited drugs or methods. World Anti-Doping
Agency (WADA), 2009 World Anti-Doping Code 12, at 34-36 (2007), availa-
ble at http://www.wada-ama.org/rtecontent/document/code-v2009_En.pdf;
Custer, supra note 25, at 206-07.
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For example, one agency may allow an athlete to compete with genetically
enhanced performance as long as the athlete used gene manipulation for
"therapeutic" purposes.158 In contrast, a different agency may decide that
such an athlete is ineligible because such gene manipulation has enhanced
"athletic performance."159 In the latter case, an athlete may be banned from
competition by the agency. 160 Without a specific stance from either the IOC
or WADA, it is difficult to draw a line between gene therapy and gene dop-
ing as a performance-enhancement or a performance-recovery method.
However, there may be one instance that helps shed light on how to evaluate
gene therapy use by athletes.
C. The Future of Performance-Enhancement via Gene Therapy:
Oscar Pisotrius
The case of Oscar Pistorius gives us a guiding example of how gene
doping may be handled in the future. Pistorius was born in Johannesburg,
South Africa, in 1986 and was missing the fibula in both legs.161 His parents
made the decision to amputate his legs halfway between his knees and ankles
when he was only eleven months old.162 When he began to walk, Pistorius
used prosthetic legs to become mobile on his own. 163 Pistorius began run-
ning competitively in 2004 using special running prosthetics called Chee-
tahs.164 In the 2006 Paralympic Athletics World Championships, he won
three gold medals in the 100, 200, and 400 meter events, setting a world
record in each event. 65 In 2008, Pistorius earned a spot on the 2008
Olympic 4x400 meter South African relay team that was expected to com-
pete in that year's Olympics.16 6 Since he qualified for such an event, Pis-
torius requested permission from the IAAF, the International Sports
Federation serving as the world governing body for track and field, to run
against "able-bodied" runners using the Cheetah prosthetics. 67
158. See generally WADA Prohibited List, supra note 8.
159. See generally id.
160. See Custer, supra note 134, at 207.
161. Josh McHugh, Blade Runner, WIRED, Mar. 2007, at 136, 138, available at
http://www.wired.com/wired/archive/15.03/blade-pr.html.
162. Id. at 138-39.
163. Id. at 139.
164. Id. at 138.
165. Gregor Wolbring, Oscar Pistorius and the Future Nature of the Olympic,
Paralymic, and Other Sports, 5 Script Ed., 139, 155 available at http://www.
law.ed.ac.uk/ahrc/scripted/vol5/wolbringasp.
166. Jere Longman, An Amputee Sprinter: Is He Disabled or Too-Abled?, N.Y.
Times, May 15, 2007, at Al, available at http:// www.nytimes.com/2007/05/
15/sports/othersports/15runner.html.
167. Wolbring, supra note 165, at 141.
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In 2007, shortly before Pistorius earned his position on the South Afri-
can Olympic team, the IAAF amended Rule 144.2 of its competition rules.168
It stated, "[T]he following shall be considered assistance, and ... therefore
not allowed: (e) use of any technical device that incorporates springs, wheels,
or any other element that provides the user with an advantage over another
athlete not using such a device."169 Since this amendment was new, the
IAAF granted Pistorius temporary permission to compete as it investigated
further as to whether his prosthetic legs would fall under the amendment's
definition of "technical device."70 The IAAF commissioned an independent
scientific study to compare the biomechanical and physiological aspects of
using the Cheetah "legs" to able-bodied runners of a similar level.171 Many
allege the study was flawed because elite athletes competing at higher levels
should have been used as a comparison to Pistorius.72 However, the study
concluded that Pistorius received an advantage by using his prosthetics, and
the IAAF ruled that he was ineligible to compete in competitions organized
under IAAF Rules. 173
Pistorius commissioned another study that reached a different conclu-
sion; he was not at an advantage using the prosthetic legs in comparison to
able-bodied runners.174 With this knowledge, Pistorius submitted an appeal
to the CAS in 2008, and requested a stay on the ban and an annulment of
IAAF's decision.175 The CAS arbitrates international sports disputes and is
used by both the IOC and WADA.176 Ultimately, the CAS determined that
the IAAF had not satisfied its burden of proof that the prosthetic legs violated
Rule 144.2(e) because there was no direct proof that Pistorius' use of the
Cheetah prosthetics gave him a metabolic or biomechanical advantage over
athletes not using prosthetics. 177 Thus, the CAS reinstated Pistorius' eligibil-
168. Peter Charlish & Stephen Riley, Should Oscar Run?, 18 FORDHAM INTELL.
PROP. MEDIA & ENT. L.J. 929, 930 (2008).
169. INTERNATIONAL AssOcIArION OF ATHLETICS FEDERATIONS (IAAF), COMPETI-
TION RULES 2008 100 (2008), available at http:// www.iaaf.org/mm/Document/
imported/42192.pdf.
170. Charlish & Riley, supra note 168, at 930-31.
171. Charlish & Riley, supra note 168 at 936-37.
172. Id. at 936-37.
173. Press Release, Int'l Ass'n of Athletics Fed'n (IAAF), Oscar Pistorius-Indep.
Scientific Study Concludes That Cheetah Prosthetics Offer Clear Mech. Ad-
vantages (Jan. 14, 2008), available at http://www.iaaf.org/news/printer,news
id=42896.htmx [hereinafter IAAF Study].
174. Wolbring, supra note 165, at 151.
175. CAS Arbitral Award, supra note 10, at 3.
176. Wolbring, supra note 165, at 149.
177. CAS Arbitral Award, supra note 10, at 15.
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ity and allowed him to compete against able-bodied athletes
internationally. 178
Such a ruling is important to the debate between performance-enhance-
ment and performance-recovery methods, such as gene therapy. This CAS
ruling provides future courts direction on how to handle such methods or
substances. The elements from this decision that are useful in analyzing fu-
ture performance-enhancing methods include: (1) eligibility review should be
on a case-by-case basis, with each case considered on its own merits; (2)
both advantages and disadvantages of the method must be weighed to deter-
mine whether the athlete has an overall advantage over other athletes; (3) the
difficulty in determining whether improved athletic ability is due to recovery
(gene therapy) or enhancement (gene doping) must be considered; and (4)
up-to-date scientific knowledge must be used for review. 179
Of these elements, the most determinative is the third element.180 Due
to the similar methods used for both gene therapy and gene doping, it may
prove quite difficult to make an exact determination on whether a substance
is solely for recovering or solely for enhancing athletic abilities. Further-
more, there are currently no tests to determine whether an athlete has used
gene therapy or gene doping techniques. One solution may be to look to the
purpose behind the gene manipulation. For instance, gene therapy seeks to
bring an injured or diseased person back to normal functioning.81 If an ath-
lete, who had been at a normal status prior to such manipulation, were to use
gene manipulation, then the athlete would be seen as trying to enhance his
athletic ability. This type of gene manipulation would render an athlete ineli-
gible for competition. On the other hand, if the athlete were to use gene
therapy and the specific area treated did not advance beyond its normal func-
tioning condition, then the athlete would remain eligible.
However, there are those that believe an athlete using gene therapy, and
who receives performance enhancement due to such therapy, should be
viewed as an athlete "recovering" and thus the athlete would have no advan-
tage over another.182 Suppose that gene therapy was the treatment prescribed
to an athlete, but it was not the athlete's choice. In that instance, the athlete
who received performance enhancement via the gene therapy recovery treat-
ment would be eligible for competition. Nevertheless, it is concerning that if
a regulatory body or court followed this reasoning, then gene therapy may
never be viewed as an illegal method even if the athlete were to obtain a
performance-enhancing advantage over other athletes. There is also the pos-
sibility that some athletes may ask their doctors to continue the gene therapy
178. Id. at 18.
179. See CAS Arbitral Award, supra note 10, at 15-16, 18.
180. See id.
181. Wolbring, supra note 165, at 155.
182. Id. at 154-55.
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beyond what is deemed necessary for injury treatment. This, of course, could
be seen as an abuse of gene therapy and may render the athlete ineligible.
The fourth element plays a secondary role to the third element, but it is
no less significant because it allows for an in-depth look into scientific ad-
vancement when considering new substances or methods. 183 Without this
element, the procedural analysis would create difficulties for future courts
attempting to determine whether a new scientific advancement creates ineli-
gibility for an athlete. Furthermore, it works in tandem with the third ele-
ment in that it allows a court to make a true distinction between performance
enhancement and performance recovery by looking at all available material
on the substance or method. 84
Next, the second element could be considered a prong of the third and is
only slightly less influential.185 Essentially, the second element is a balanc-
ing test that asks the court to weigh the "advantages and disadvantages of the
method" in order to determine if the athlete's use of that method creates an
advantage over other athletes.186 The reason the second element could be a
prong of the third element is that the two elements play off each other. To
determine whether the athlete has achieved an advantage over another athlete
through the use of a certain method, the court must decide whether that
method has truly enhanced the athlete's performance beyond that which was
normal before use of the method. However, without the second element in-
cluded in the court's analysis, the third element would not have as much
merit standing alone.187
Lastly, the first element is a complementary addition to elements two,
three and four.188 The analysis would be incomplete and unfair to the athlete
without "each case [being] considered on its own merits . ."189 The more
specific or detailed a certain scientific advancement is, then the more need
there is to consider each athlete's situation on its own. Furthermore, there
may be circumstances surrounding the athlete's use of a new substance or
method that are only directly related to his or her personal situation. It would
be unfair to compare an athlete's use of one method to another athlete's use
of the same method, but in a different sporting contest, because that is similar
to comparing apples to oranges. Moreover, this element helps create a
broader analysis for future courts because no one set of circumstances or
personal situations are equal.190 Clearly, the court was looking to create an
183. See CAS Arbitral Award, supra note 10, at 16, 18.
184. See id. at 15-16, 18.
185. See id.
186. Id. at 14.
187. See id. at 15-16, 18.
188. See id.
189. CAS Arbitral Award, supra note 10, at 16.
190. See id.
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element that would treat athletes fairly and uniquely, which is of utmost im-
portance when court decisions could determine the future of an athlete's
livelihood.
In conclusion, the case of Oscar Pistorius provides an important proce-
dural map for determining whether a method or substance is truly enhancing
an athlete's performance or simply assisting that athlete in recovery.' 9' Due
to the similarity between Pistorius' prosthetic Cheetah legs enhancement and
gene therapy patients receiving genetic enhancements, the CAS ruling pro-
vides a procedural map for regulating bodies such as the IOC, WADA, and
IAAF to follow.192 Even though the CAS ruling does not directly deal with
gene therapy, it does offer four elements for regulatory agencies worldwide
to use in fairly assessing whether a technological or biological advancement
used by athletes is truly assisting them in recovery or enhancing athletic per-
formance.93 It may not be much guidance, but at this point there is at least
some guidance to future courts on the issue. As more scientific and biologi-
cal advances are made, the Pistorius analysis should provide the base from
which other courts can expand.194 Under the CAS Panel's analysis, the fu-
ture of performance-enhancement may change drastically from what we rec-
ognize today.
V. CONCLUSION
If regulatory agencies and Congress are to truly make a stand and estab-
lish bright-line rules regarding performance-enhancing and performance-re-
covery methods and substances, then changes such as those exhibited by the
CAS ruling need to be followed consistently.'95 However, unlike past legis-
lation that bans specific methods or substances, future decisions regarding
performance enhancement should allow for the consideration that the sub-
stance or method may be used for recovery or even medical purposes only. 196
The CAS Panel's decision indicates that consideration will need to be on a
case-by-case basis, as evidenced by the first element in the CAS decision.197
However, that element alone will not suffice for handling future performance
enhancement and eligibility disputes in international sports.
In a pattern we see in nearly every sport, athletes are going to find the
most innovative ways to recover from grueling competition, even if that re-
covery method crosses the line into possible athletic enhancement.198 Cur-
191. See id. at 16, 18.
192. See id.
193. See id. at 15-16, 18.
194. See id. at 15-16, 18.
195. See CAS Arbitral Award, supra note 10, at 15-16, 18.
196. See Drug Control Act, supra note 2.
197. CAS Arbitral Award, supra note 10, at 16.
198. See Bonds, WL 618911, at *1; see also NPR Armstrong Article, supra note 91.
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rent legislation attempts to ban all types of methods and substances, even
though some of these may, in fact, benefit athletes in the form of perform-
ance recovery. 199 Several new substances and methods are already being
used by doctors and physicians to treat specific diseases and illnesses. This
practice of experimenting in the medical field directly affects performance
recovery and, inevitably, enhancement in athletics. Thus, one important step
in distinguishing between performance enhancement and performance recov-
ery is to strictly adhere to the procedural requirements outlined in the CAS
Panel's ruling for Pistorius until further analysis is created by future court
decisions.200 At the very least, some consistency will be established within
the realm of international sports despite the rapid advancements that occur
with performance-enhancement or performance-recovery use by athletes.
Although using the CAS decision's procedural requirements is impor-
tant to future decisions regarding performance enhancement, it is also vital
that athletes be aware of what is motivating them to try such substances or
methods.01 Early athletes, as far back as the first Olympians, were already
testing substances that could possibly enhance their performance in competi-
tion.202 Such use was not necessarily frowned upon centuries ago, but it has
recently become the center of heated debate and litigation.2o3 The present-
day athlete must be aware of every possible repercussion from choosing to
try new methods of recovery because it is not yet completely clear how that
method will be treated by regulatory bodies. At this point, the only clarity is
that any substance already known to either damage the health of an athlete
when used in excess or greatly enhance the athlete's abilities beyond that of a
normal level will be considered banned. Consequently, the athlete will be
deemed ineligible for competition. Due to the lack of clarity and the few
decisions rendered on cutting-edge performance-enhancing substances and
drugs, it is difficult for an athlete, coach, trainer, parent, or agent to predict
whether new developments or methods will preclude the athlete from partici-
pating in competition. Therefore, athletes should take the time to educate
themselves and their team and consider whether they want to risk jeopardiz-
ing their careers or futures when attempting to use new methods or sub-
stances to aid in recovery.
Technological and scientific advancement is moving forward at an ex-
ponential rate while regulations governing these new advancements are at-
tempting to keep pace. In other words, new methods and substances are
advancing, just as they have been for centuries. These facts, and the changes
that will come about in the coming decades, may make the current procedure
for dealing with performance-enhancing substances and methods unrealistic
199. See Drug Control Act, supra note 2.
200. See CAS Arbitral Award, supra note 10, at 18.
201. See id. at 15-16, 18.
202. History of PE Drugs, supra note 3.
203. See Bonds, WL 618911, at *1; see also NPR Armstrong Article, supra note 91.
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and perhaps irrelevant.204 Furthermore, the current all-encompassing ban-
ning of nearly every substance that could possibly enhance athletic perform-
ance, even if it also helps with sports injury, is without deep thought.
Considering their reasonableness, it is necessary and justifiable to follow pro-
cedures like those given in the CAS ruling for Pistorius. 205
Looking forward into the future of sports performance, it is inevitable
that scientific progress will be made and that athletes will attempt to use the
advancements to assist in them. Thus, it is vital that we consistently apply
reasonable procedural requirements in order to do justice to the athletes, their
competitors, and the scientific advancements in both performance enhance-
ment and recovery methods.2 06 In the future, we may even discover that
there really is no difference between a method or substance that assists in
recovery and enhances athletic abilities, rendering the legal and scientific
paradox altogether moot.
204. See CAS Arbitral Award, supra note 10, at 15-16, 18.
205. See id. at 18.
206. See id. at 15-16, 18.
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